Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase

被引:41
作者
Ban, Hyun Seung [1 ]
Usui, Taikou [1 ]
Nabeyama, Wataru [1 ]
Morita, Hidetoshi [2 ]
Fukuzawa, Kaori [3 ]
Nakamura, Hiroyuki [1 ]
机构
[1] Gakushuin Univ, Fac Sci, Dept Chem, Tokyo 1718588, Japan
[2] Yamagata Univ, Grad Sch Sci & Engn, Yamagata 9908560, Japan
[3] Mizuho Informat & Res Inst Inc, Tokyo 1018443, Japan
基金
日本科学技术振兴机构;
关键词
GROWTH-FACTOR RECEPTOR; MOLECULAR-ORBITAL METHOD; APPROXIMATE COMPUTATIONAL METHOD; IRREVERSIBLE INHIBITORS; ACQUIRED-RESISTANCE; ANTITUMOR-ACTIVITY; ESTROGEN-RECEPTOR; QUANTUM-MECHANICS; PROTEASOME; APOPTOSIS;
D O I
10.1039/b909504g
中图分类号
O62 [有机化学];
学科分类号
070303 ; 081704 ;
摘要
Boron-conjugated 4-anilinoquinazolines were designed and synthesized as inhibitors of EGFR tyrosine kinase with possible covalent bond interactions between the boron atom and the nucleophilic groups of the EGFR kinase domain. Among the compounds synthesized, compounds 6c, 7b, and 7d reduced the EGF-mediated phosphorylation of EGFR tyrosine kinase and its downstream kinases including ERK and Akt in A431 cells. The cell growth was inhibited by these compounds through arrest of G1 cell cycle, which induced apoptosis. A time-dependent in vitro preincubation assay demonstrated the irreversible inhibition of compound 7d against EGFR tyrosine kinase. Quantum mechanical docking simulation revealed that the boronic acid moiety of compound 7d formed a covalent B-O bond with Asp800 in addition to hydrogen bonds with Asp800 and Cys797, which may cause the prolonged inhibition of compound 7d toward EGFR tyrosine kinase.
引用
收藏
页码:4415 / 4427
页数:13
相关论文
共 47 条
[1]  
[Anonymous], 2017, J MOL STRUCT, DOI DOI 10.1016/J.MOLSTRUC.2017.03.014
[2]  
Barbacci EG, 2003, CANCER RES, V63, P4450
[3]   Structure-guided development of affinity probes for tyrosine kinases using chemical genetics [J].
Blair, Jimmy A. ;
Rauh, Daniel ;
Kung, Charles ;
Yun, Cai-Hong ;
Fan, Qi-Wen ;
Rode, Haridas ;
Zhang, Chao ;
Eck, Michael J. ;
Weiss, William A. ;
Shokat, Kevan M. .
NATURE CHEMICAL BIOLOGY, 2007, 3 (04) :229-238
[4]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[5]   Tyrosine kinase inhibitors .8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor [J].
Bridges, AJ ;
Zhou, H ;
Cody, DR ;
Rewcastle, GW ;
McMichael, A ;
Showalter, HDH ;
Fry, DW ;
Kraker, AJ ;
Denny, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (01) :267-276
[6]  
COTTON FA, 1987, BASIC INORGANIC CHEM, P257
[7]  
COTTON FA, 1987, BASIC INORGANIC CHEM, P7
[8]  
DECKER SJ, 1992, J BIOL CHEM, V267, P1104
[9]   Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785) [J].
Discafani, CM ;
Carroll, ML ;
Floyd, MB ;
Hollander, IJ ;
Husain, Z ;
Johnson, BD ;
Kitchen, D ;
May, MK ;
Malo, MS ;
Minnick, AA ;
Nilakantan, R ;
Shen, R ;
Wang, YF ;
Wissner, A ;
Greenberger, LM .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (08) :917-925
[10]   Assessment of HER2 status in breast cancer: why, when and how? [J].
Dowsett, M ;
Cooke, T ;
Ellis, I ;
Gullick, WJ ;
Gusterson, B ;
Mallon, E ;
Walker, R .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (02) :170-176